+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dyskinesia (Central Nervous System) - Drugs In Development, 2021

  • ID: 5402690
  • Report
  • July 2021
  • Region: Global
  • 294 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Celon Pharma SA
  • Hua Medicine Shanghai Ltd
  • Medytox Inc
  • Nissan Chemical Corp
  • Revance Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Drugs In Development, 2021, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 15, 8, 1, 31 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Celon Pharma SA
  • Hua Medicine Shanghai Ltd
  • Medytox Inc
  • Nissan Chemical Corp
  • Revance Therapeutics Inc

Introduction
Dyskinesia - Overview
  • Dyskinesia - Therapeutics Development
Dyskinesia - Therapeutics AssessmentDyskinesia - Companies Involved in Therapeutics DevelopmentDyskinesia - Drug ProfilesDyskinesia - Dormant ProjectsDyskinesia - Discontinued ProductsDyskinesia - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Dyskinesia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Dyskinesia - Pipeline by Addex Therapeutics Ltd, 2021
  • Dyskinesia - Pipeline by AEON Biopharma Inc, 2021
  • Dyskinesia - Pipeline by AfaSci Inc, 2021
  • Dyskinesia - Pipeline by Amarantus Bioscience Holdings Inc, 2021
  • Dyskinesia - Pipeline by Astraea Therapeutics LLC, 2021
  • Dyskinesia - Pipeline by Bod Australia Ltd, 2021
  • Dyskinesia - Pipeline by Cannabis Science Inc, 2021
  • Dyskinesia - Pipeline by Celon Pharma SA, 2021
  • Dyskinesia - Pipeline by Cerevance Inc, 2021
  • Dyskinesia - Pipeline by Cerevel Therapeutics Holdings Inc, 2021
  • Dyskinesia - Pipeline by Contera Pharma ApS, 2021
  • Dyskinesia - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Dyskinesia - Pipeline by DanPET AB, 2021
  • Dyskinesia - Pipeline by Domain Therapeutics SA, 2021
  • Dyskinesia - Pipeline by EpiVax Inc, 2021
  • Dyskinesia - Pipeline by GraySpace Therapeutics Inc, 2021
  • Dyskinesia - Pipeline by Hua Medicine Shanghai Ltd, 2021
  • Dyskinesia - Pipeline by Ipsen SA, 2021
  • Dyskinesia - Pipeline by IRLAB Therapeutics AB, 2021
  • Dyskinesia - Pipeline by Jazz Pharmaceuticals Plc, 2021
  • Dyskinesia - Pipeline by Junaxo Inc, 2021
  • Dyskinesia - Pipeline by MapLight therapeutics Inc, 2021
  • Dyskinesia - Pipeline by Medytox Inc, 2021
  • Dyskinesia - Pipeline by Melior Pharmaceuticals II LLC, 2021
  • Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, 2021
  • Dyskinesia - Pipeline by MitoDys Therapeutics Ltd, 2021
  • Dyskinesia - Pipeline by Molomics Biotech SL, 2021
  • Dyskinesia - Pipeline by Motac Neuroscience Ltd, 2021
  • Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, 2021
  • Dyskinesia - Pipeline by Neurocea Pharmaceuticals, 2021
  • Dyskinesia - Pipeline by Neurocrine Biosciences Inc, 2021
  • Dyskinesia - Pipeline by Neurolixis Inc, 2021
  • Dyskinesia - Pipeline by Newron Pharmaceuticals SpA, 2021
  • Dyskinesia - Pipeline by Nissan Chemical Corp, 2021
  • Dyskinesia - Pipeline by Novartis AG, 2021
  • Dyskinesia - Pipeline by OB Pharmaceuticals, 2021
  • Dyskinesia - Pipeline by Peptron Inc, 2021
  • Dyskinesia - Pipeline by PharmaTher Holdings Ltd, 2021
  • Dyskinesia - Pipeline by PolyCore Therapeutics LLC, 2021
  • Dyskinesia - Pipeline by Praxis Precision Medicines Inc, 2021
  • Dyskinesia - Pipeline by Revance Therapeutics Inc, 2021
  • Dyskinesia - Pipeline by Sage Therapeutics Inc, 2021
  • Dyskinesia - Pipeline by SalubRx Therapeutics Inc, 2021
  • Dyskinesia - Pipeline by Shionogi & Co Ltd, 2021
  • Dyskinesia - Pipeline by Sinopia Biosciences Inc, 2021
  • Dyskinesia - Pipeline by SOM Biotech SL, 2021
  • Dyskinesia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
  • Dyskinesia - Pipeline by Tempero Bio, 2021
  • Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Dyskinesia - Pipeline by Trevi Therapeutics Inc, 2021
  • Dyskinesia - Pipeline by Ultragenyx Pharmaceutical Inc, 2021
  • Dyskinesia - Pipeline by VistaGen Therapeutics Inc, 2021
  • Dyskinesia - Dormant Projects, 2021
  • Dyskinesia - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Dyskinesia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Addex Therapeutics Ltd
  • AEON Biopharma Inc
  • AfaSci Inc
  • Amarantus Bioscience Holdings Inc
  • Astraea Therapeutics LLC
  • Bod Australia Ltd
  • Cannabis Science Inc
  • Celon Pharma SA
  • Cerevance Inc
  • Cerevel Therapeutics Holdings Inc
  • Contera Pharma ApS
  • Daewoong Pharmaceutical Co Ltd
  • DanPET AB
  • Domain Therapeutics SA
  • EpiVax Inc
  • GraySpace Therapeutics Inc
  • Hua Medicine Shanghai Ltd
  • Ipsen SA
  • IRLAB Therapeutics AB
  • Jazz Pharmaceuticals Plc
  • Junaxo Inc
  • MapLight therapeutics Inc
  • Medytox Inc
  • Melior Pharmaceuticals II LLC
  • Merz Pharma GmbH & Co KgaA
  • MitoDys Therapeutics Ltd
  • Molomics Biotech SL
  • Motac Neuroscience Ltd
  • Neurim Pharmaceuticals Ltd
  • Neurocea Pharmaceuticals
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Newron Pharmaceuticals SpA
  • Nissan Chemical Corp
  • Novartis AG
  • OB Pharmaceuticals
  • Peptron Inc
  • PharmaTher Holdings Ltd
  • PolyCore Therapeutics LLC
  • Praxis Precision Medicines Inc
  • Revance Therapeutics Inc
  • Sage Therapeutics Inc
  • SalubRx Therapeutics Inc
  • Shionogi & Co Ltd
  • Sinopia Biosciences Inc
  • SOM Biotech SL
  • Sumitomo Dainippon Pharma Co Ltd
  • Tempero Bio
  • Teva Pharmaceutical Industries Ltd
  • Trevi Therapeutics Inc
  • Ultragenyx Pharmaceutical Inc
  • VistaGen Therapeutics Inc
Note: Product cover images may vary from those shown